Non-Hodgkin lymphoma

This study tests whether bone marrow from deceased donors can be used to treat people with blood cancers like leukemia and lymphoma. Participants receive a transplant of cryopreserved marrow from a deceased donor or standard cells from a living donor. The goal is to see if the de…

This Phase 2 trial is testing an experimental therapy called LMY-920, which uses a patient's own immune cells (T cells) engineered to recognize and attack cancer cells through a protein called BAFF. The study aims to see if this treatment can shrink tumors or eliminate signs of c…

This trial tests whether giving anti-inflammatory drugs directly into the spinal fluid at the first sign of a brain-related side effect can stop it from becoming severe. The study enrolls adults with non-Hodgkin lymphoma who are receiving CD19 CAR T cell therapy, a treatment that…

This early-phase trial tests a new approach using donor immune cells that have been mobilized through exercise to prevent or treat leukemia relapse after a stem cell transplant. The study will enroll 94 people with various blood cancers. Some will receive the exercise-mobilized c…

This phase 1 trial is testing a new kind of CAR-T cell therapy, called LMY-922, for people with certain blood cancers that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called BAFF on cancer cells. The study aims to …

This study tests a special way to process donated stem cells to make transplants safer for people with leukemia or lymphoma. The goal is to reduce serious complications like graft-versus-host disease, where donor cells attack the patient's body. About 100 participants will receiv…

This study looks at whether using a cousin as a stem cell donor works as well as using a sibling for people with blood cancers. Researchers will compare survival, relapse, and side effects like graft-versus-host disease in patients who received a transplant from either a cousin o…

This study will follow 70 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who are receiving bispecific antibody therapy. Researchers want to understand why some patients don't respond or develop serious side effects. They will look at tumor samples, gut bacteria, a…

This study will follow 1,000 people newly diagnosed with lymphoma to collect information on their treatments and outcomes. The goal is to learn which strategies work best in real-world settings, not to test a new drug. Participants must be at least 16 years old and have measurabl…

This study will check for a mutation in the Notch1 gene in blood or bone marrow samples from 80 people with chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL). The goal is to see how common this mutation is and compare it between the two cancers. This is an observ…